Clinical trials
Anemia of Chronic Kidney Disease clinical trials
Below are recruiting anemia of chronic kidney disease clinical trials, each written for real people, not researchers. We’re tracking 57 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07119372RecruitingPhase 3
New drug for anemia from kidney disease on dialysis
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
MinskAges 18–75 - NCT07123909Recruiting
Immune adsorbent therapy for dialysis patients with inflammation
This study tests a therapy that absorbs inflammatory substances from the blood during dialysis. It may help people on dialysis who have ongoing inflammation, shown by high IL-6 or CRP levels.
MoscowAges 18 years+ - NCT07368946Recruiting
Phosphate study for people with kidney disease
This study looks at how the body handles phosphate in people with chronic kidney disease. It may help researchers understand how to better manage phosphate levels to improve health.
Dallas, TexasAges 18 years+ - NCT02411773RecruitingPhase 1
Test a nerve-blocking medicine in kidney disease
This Phase 1 study tests whether a medicine that reduces nerve signals (“sympatholysis”) is safe and how it affects people with chronic kidney disease. It may help researchers understand new ways to protect the kidneys, but the main goal here is safety.
Decatur, GeorgiaAges 18–75 - NCT02947750RecruitingPhase 2
Exercise study in people with kidney disease
This Phase 2 study tests how engaging in supervised exercise affects the body’s blood-vessel responses in people with chronic kidney disease (CKD) who don’t exercise regularly. It may help researchers understand whether exercise could be beneficial for CKD-related health changes.
Atlanta, GeorgiaAges 18–75 - NCT07483372RecruitingPhase 1
SC101 injection for resistant hypertension with kidney disease
This early-phase trial tests an injection called SC101 into the fat around your kidney. It aims to help lower blood pressure in people whose hypertension is poorly controlled despite multiple medications and who have moderate to severe chronic kidney disease.
Suzhou, JiangsuAges 18–65 - NCT07487727RecruitingPhase 3
Study of an experimental anemia drug for chronic kidney disease patients not on dialysis
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT07577817RecruitingEarly Phase 1
Safety Study of CTX001 in Healthy Adults
This early-stage study tests a new experimental drug called CTX001 in healthy volunteers to check if it is safe and well-tolerated. Researchers will also measure how your body processes the drug and how it affects certain blood markers.
Melbourne, VictoriaAges 18–55 - NCT06621264Recruiting
Exercise study to improve walking in kidney and artery disease
This trial tests whether a supervised exercise program can help people with chronic kidney disease and peripheral artery disease walk better and feel stronger. It aims to improve mobility and quality of life.
Ferrara, ItalyAges 18–80 - NCT05189925RecruitingPhase 1
Correcting a missing immune enzyme using an mRNA cell therapy
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
Bethesda, MarylandAges 18–75 - NCT07496177RecruitingPhase 2
HTD1801 for kidney function in diabetes and kidney disease
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
Weifang, ShandongAges 18–75 - NCT04819217Recruiting
Probiotics and a toxin binder to slow chronic kidney disease
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
TaipeiAges 20 years+ - NCT07333313Recruiting
Study of oral medicine and probiotics for kidney disease in diabetes
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Taipei, TaiwanAges 20 years+ - NCT06310967RecruitingPhase 1/Phase 2
Study of IG3018 for high uric acid with or without kidney disease
This trial tests a new medicine, IG3018, to lower high uric acid levels in people with or without chronic kidney disease. It aims to find the right dose and see if it's safe.
Botany, New South WalesAges 18–75 - NCT07134335RecruitingPhase 2
Study of UBT251 injection for chronic kidney disease
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
BeijingAges 18–75 - NCT07413315Recruiting
Kidney rehab program for dialysis patients after hospital stay
This study tests a special exercise and education program for people on daily hemodialysis (a type of kidney treatment) who have recently been in the hospital. The goal is to see if this program helps you recover and feel better.
BrusselsAges 18 years+ - NCT06788054Enrolling by invitation
Exercise during dialysis for fitness and survival
This study tests whether adding exercise during your dialysis sessions can improve your physical fitness, body composition, and survival. If you are on hemodialysis and meet the health criteria, you would either exercise while on the machine or receive standard care.
León, GuanajuatoAges 18–50 - NCT04986332Recruiting
Program for COPD or heart failure in people with other illnesses
This trial studies a detailed, whole-body program to improve outcomes in people with COPD or heart failure, especially those who also have several other chronic conditions. It may help by improving activity and monitoring health markers over about 24 weeks.
PalermoAges 45–75 - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Washington D.C., District of ColumbiaAges 4 weeks–18 years - NCT06542393RecruitingPhase 2
Blood management for anemic patients having bypass surgery
This trial tests a blood management strategy to help people with anemia who are having coronary artery bypass surgery (CABG). If you qualify, you may receive a treatment to improve your blood counts before surgery, which could reduce the need for transfusions.
São Paulo, São PauloAges 18–80 - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT05715814RecruitingPhase 3
Test diabetes-pill type medicine on kidney dialysis safety
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
Toronto, OntarioAges 18 years+
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for anemia of chronic kidney disease?
- Yes. Clin2 currently lists 57 recruiting anemia of chronic kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a anemia of chronic kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a anemia of chronic kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.